June 25 (Reuters) - Kymera Therapeutics Inc KYMR.O:
KYMERA THERAPEUTICS ANNOUNCES SANOFI IRAK4 COLLABORATION UPDATE
KYMERA THERAPEUTICS INC - SANOFI TO ADVANCE KYMERA'S KT-485 INTO CLINICAL TESTING
KYMERA THERAPEUTICS INC - ELIGIBLE FOR UP TO $975 MILLION IN MILESTONES
KYMERA THERAPEUTICS INC - KT-485 SHOWS INCREASED SELECTIVITY AND POTENCY IN PRECLINICAL TESTING
Source text: ID:nGNXc1jhqZ
Further company coverage: KYMR.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.